Dry Eye Disease Market Size in the 7MM was ~USD 3,759 Million in 2023, it is expected to grow by 2034, according to DelveInsight

The Dry Eye Disease Market in the 7MM was valued at ~USD 3,759 Million in 2023, over the study period from 2020 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Dry Eye Disease Market Landscape. By analyzing historical data, current Dry Eye Disease Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Dry Eye Disease Market is increasingly guided by biomarker-driven strategies. Dry Eye Disease (DED), also known as keratoconjunctivitis sicca, is a common chronic condition in which the eyes do not produce enough tears or the tears evaporate too quickly. This leads to insufficient lubrication and moisture on the surface of the eye. The tear film—made of oil, water, and mucus—becomes unstable, resulting in irritation, inflammation, and visual disturbances. People with dry eye may experience burning, stinging, grittiness, redness, blurred vision, sensitivity to light, and a feeling of something “in the eye.”

DelveInsight’s report, “Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Dry Eye Disease Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Dry Eye Disease Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Dry Eye Disease Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Dry Eye Disease Market Forecast

Key Takeaways from Dry Eye Disease Market Report

• The leading Dry Eye Disease Companies, such as Palatin Technologies, Inc., Aldeyra Therapeutics, Inc., ReGenTree/RegeneRx Biopharmaceuticals, Inc., Mimetogen, Alcon/Aerie Pharmaceuticals, BRIM Biotechnology, Inc., Seikagaku Corporation, Mitotech, Senju Pharmaceutical, Sylentis, S.A./PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll BioPharma Co., Ltd./Daewoong Pharmaceutical Co. Ltd., Redwood Pharma AB, AxeroVision, Inc., OKYO Pharma, AxeroVision, Inc., AxeroVision, Inc., Glaukos Corporation, Oculis, and others.
• Promising Dry Eye Disease Therapies such as TJO-083, Diquafosol ophthalmic sodium solution 3%, ALY688 Ophthalmic Solution, Brimonidine, SHJ002, INV-102, Reproxalap Ophthalmic Solution (0.25%), licaminlimab, INV-102, and others.
• The Dry Eye Disease Market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching multiple-stage Dry Eye Disease Pipeline products will significantly revolutionize the Dry Eye Disease Market Dynamics.

Dry Eye Disease Overview

Dry Eye Disease (DED) is a common, chronic condition in which the eyes do not produce enough tears or the tears evaporate too quickly, leading to inadequate lubrication of the eye surface. This imbalance in the tear film causes inflammation, discomfort, and potential damage to the ocular surface. People with dry eye often experience symptoms such as burning, stinging, grittiness (feeling like something is in the eye), redness, blurred vision, sensitivity to light, and eye fatigue—especially during activities like reading, screen use, or driving. The condition can be caused by aging, hormonal changes, autoimmune disorders (such as Sjögren’s syndrome), environmental factors, prolonged digital device use, certain medications, or dysfunctional meibomian glands.

Get a Free sample for the Dry Eye Disease Market Report @ https://www.delveinsight.com/report-store/dry-eye-disease-market-insights 

Key Trends in the Dry Eye Disease Market

• Rising Global Prevalence Driving Market Demand

Dry Eye Disease continues to grow as a major ophthalmic concern due to aging populations, increased screen exposure, environmental pollution, contact lens overuse, and higher diagnosis rates. The rise of lifestyle-driven ocular surface disorders is significantly expanding the patient pool.

• Transition toward Targeted and Mechanism-Based Therapies

Traditional therapies focused on symptomatic relief, but the market is shifting toward inflammation-modulating, tear-film–stabilizing, and regenerative approaches. Novel therapies targeting meibomian gland dysfunction (MGD), cytokine pathways, and neurosensory abnormalities are gaining strong momentum.

• Strong Pipeline Activity in Novel Formulations and Delivery Technologies

Companies are developing innovative delivery systems such as nanomicellar formulations, water-free drops, preservative-free solutions, punctal plugs, and advanced inserts. These systems enhance ocular bioavailability, improve retention time, and reduce treatment burden.

• Surge in Biologics and Immunomodulators

The pipeline is increasingly populated with biologic agents, recombinant proteins, and advanced immunomodulators targeting disease-driving inflammation. These next-generation therapies promise longer-lasting efficacy and improved outcomes compared with conventional lubricants.

• Growing Adoption of Digital Diagnostics & AI-Based Tools

Automated tear-film analysis, noninvasive imaging, AI-driven ocular surface pattern recognition, and remote monitoring tools are improving diagnosis accuracy and enabling early intervention. This technological integration is reshaping treatment workflows.

• Increased Commercial Interest & Strategic Collaborations

The DED space is witnessing rising M&A, licensing deals, and strategic partnerships as pharma companies aim to strengthen their ophthalmology portfolios. Collaboration between biotech firms, device makers, and drug developers is accelerating innovation.

• Emphasis on Personalized and Combination Therapy Approaches

Clinicians increasingly prefer tailored treatment strategies, combining anti-inflammatory drugs, lubricants, MGD therapies, and lifestyle modifications. The shift toward personalized regimens supports long-term disease control and boosts therapy adoption.

• Expansion of OTC and Consumer-Focused Eye Care Products

The market is seeing significant growth in OTC lubricants, preservative-free formulations, and advanced artificial tears, driven by consumer awareness and self-care trends. Retail channels and e-commerce are expanding the market footprint.

• Advancements in Regenerative and Neuroprotective Therapies

Emerging candidates focus on corneal nerve regeneration, tear gland repair, and ocular surface healing, signaling a move from symptomatic management to disease-modifying therapies. These innovations could redefine the DED treatment landscape.

• Strong Market Growth across Key Regions

North America dominates due to high diagnosis rates and strong product uptake, while Europe and Asia-Pacific markets are expanding rapidly through improved eye-care access, awareness initiatives, and increased product approvals.

Dry Eye Disease Epidemiology Segmentation in the 7MM

The Dry Eye Disease Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into-

• Total Diagnosed Dry Eye Disease Prevalence
• Gender-specific Diagnosed Dry eye disease prevalence
• Age-specific Diagnosed Prevalent Cases
• Severity-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Dry Eye Disease Epidemiology trends @ Dry Eye Disease Epidemiology Forecast

Recent Development in the Dry Eye Disease Treatment Landscape

• In December 2025, Instituto Grifols, S.A. conducted a Phase 2, multi-site, double-masked, randomized, vehicle-controlled study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.
• In December 2025, BioTissue Holdings Inc. initiated a study to evaluate the safety and efficacy of TTAX03 in participants with mild to moderate DED. After confirmation of inclusion and exclusion criteria, all eligible patients will be randomized in a 1:1:1:1 ratio to receive one of the three doses of TTAX03 (10 mg of TTAX03 reconstituted in 150, 300, or 600 uL saline, i.e., subgroup A, B, and C, respectively) or to the saline control group (subgroup D). For all four groups, the same volume of reconstituted solution will be applied to the concave bowl of a bandage contact lens and inserted into the eye. The more severe eye will serve as the study eye, which meets inclusion and exclusion criteria.

Dry Eye Disease Companies and Therapies

• Taejoon Pharmaceutical Co. Ltd: TJO-083
• BioTheraVision, Inc.: BTV100
• VivaVision Biotech Inc.: VVN001 Ophthalmic Solution, 5%
• Allysta Pharmaceutical: ALY688 Ophthalmic Solution
• Ocugen: Brimonidine

To know more about Dry Eye Disease Companies working in the treatment market, visit @ Dry Eye Disease Clinical Trials and Therapeutic Assessment

Dry Eye Disease Market Drivers

• Growing Disease Burden

The rising prevalence of Dry Eye Disease (DED) across all major markets—driven by aging populations, increased screen time, and environmental pollutants—is significantly accelerating market expansion. Higher diagnosis rates and increased awareness among patients and physicians are pushing more individuals into the treatment pool.

• Advancements in Diagnostic Technologies

Innovations such as tear osmolarity testing, meibography, and point-of-care devices have enhanced early and accurate diagnosis of DED. Improved detection encourages timely intervention, boosting the demand for therapeutic solutions.

• Expansion of Therapeutic Options

Introduction of next-generation anti-inflammatory drugs, tear film stabilizers, regenerative therapies, and neurosensory-targeting agents is transforming the treatment landscape. Novel mechanisms of action and long-lasting formulations are attracting both clinicians and patients.

• Increasing Adoption of Prescription Therapies

Growing use of prescription drugs like anti-inflammatory agents, secretagogues, and biologics is driving revenue growth. The shift from over-the-counter (OTC) management to prescription-based treatment is a key market driver.

• Strong R&D Pipeline

A promising pipeline featuring novel candidates targeting ocular surface inflammation, tear production, and meibomian gland dysfunction is expected to fuel future market growth. Strategic collaborations and accelerated regulatory pathways are further boosting development.

• Technological Integration in Treatment

Advancements in device-based therapies, including intense pulsed light (IPL) systems and thermal pulsation technologies, are creating new revenue streams. Combination therapies (drug + device) are gaining traction, improving patient outcomes and market acceptance.

• Growing Awareness and Patient Education

Increased awareness through patient advocacy groups, eye-health campaigns, and digital health platforms is encouraging more individuals to seek timely care. Greater emphasis on quality-of-life impact is prompting earlier clinical intervention.

Dry Eye Disease Market Barriers

• Complex and Multifactorial Pathophysiology

DED arises from a combination of tear film instability, inflammation, meibomian gland dysfunction, and environmental triggers. This multifactorial nature makes it difficult for drug developers to identify single, targeted treatment pathways, slowing innovation and reducing success rates in clinical trials.

• High Disease Heterogeneity among Patients

Patients experience varied symptoms, severity levels, and underlying causes. This heterogeneity complicates patient stratification, makes clinical trial population selection challenging, and leads to inconsistent treatment responses.

• Lack of Reliable and Unified Diagnostic Tools

DED diagnosis still relies on subjective symptom scores and semi-quantitative clinical tests, such as Schirmer’s test or tear breakup time. The absence of standardized, universally accepted biomarkers reduces diagnostic accuracy and increases the risk of misclassification in research studies.

• Limited Efficacy of Existing Therapies

Available therapies often provide only partial or temporary relief. Many treatments fail to address the underlying inflammatory and evaporative components comprehensively, resulting in unmet needs and patient dissatisfaction.

• Long Treatment Duration and Compliance Challenges

DED therapies typically require long-term, consistent application. Many patients drop off treatment due to delayed onset of action, burning sensations with eye drops, or high dosing frequency—creating adherence issues and limiting real-world effectiveness.

• Challenges in Demonstrating Clinical Endpoints

Regulatory bodies require improvements in both signs and symptoms for drug approval. However, signs and symptoms often do not correlate strongly, making it difficult for developers to meet dual-endpoint criteria in clinical trials.

• High Costs of Innovative Therapies

Advanced biologics, novel anti-inflammatory agents, and regenerative approaches come with high development and commercialization costs. Pricing pressures and reimbursement challenges limit accessibility for patients and discourage investment from small and mid-sized companies.

• Competition in a Crowded Therapeutics Landscape

Although unmet needs exist, the market already contains a broad range of artificial tears, anti-inflammatories, and device-based solutions. Differentiating new therapies in this competitive environment requires strong clinical evidence, which can be difficult to generate.

• Awareness Gaps Among Patients and Providers

Many patients underreport symptoms, and some clinicians underestimate disease severity. This delay in diagnosis and intervention reduces the potential market for emerging therapies.

• Environmental & Lifestyle Factors Complicating Management

External contributors—screen exposure, pollution, contact lens use, and aging—continue to drive DED incidence. These non-modifiable or hard-to-control factors make long-term disease control challenging, thereby affecting treatment outcomes and market penetration.

Scope of the Dry Eye Disease Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Dry Eye Disease Companies- Palatin Technologies, Inc., Aldeyra Therapeutics, Inc., ReGenTree/RegeneRx Biopharmaceuticals, Inc., Mimetogen, Alcon/Aerie Pharmaceuticals, BRIM Biotechnology, Inc., Seikagaku Corporation, Mitotech, Senju Pharmaceutical, Sylentis, S.A./PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll BioPharma Co., Ltd./Daewoong Pharmaceutical Co. Ltd., Redwood Pharma AB, AxeroVision, Inc., OKYO Pharma, AxeroVision, Inc., AxeroVision, Inc., Glaukos Corporation, Oculis, and others.
• Dry Eye Disease Therapies- TJO-083, Diquafosol ophthalmic sodium solution 3%, ALY688 Ophthalmic Solution, Brimonidine, SHJ002, INV-102, Reproxalap Ophthalmic Solution (0.25%), licaminlimab, INV-102, and others.
• Dry Eye Disease Therapeutic Assessment: Dry Eye Disease current marketed and Dry Eye Disease emerging therapies
• Dry Eye Disease Market Dynamics: Dry Eye Disease market drivers and Dry Eye Disease market barriers
• Dry Eye Disease Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Dry Eye Disease Unmet Needs, KOL’s views, Analyst’s views, Dry Eye Disease Market Access and Reimbursement

Discover more about therapies set to grab major Dry Eye Disease Market Share @ Dry Eye Disease Treatment Market

Table of Contents

1. Key Insights

2. Dry Eye Disease Market Report Introduction

3. Dry Eye Disease Market Overview at a Glance

4. Dry Eye Disease Executive Summary

5. Key Events

6. Dry Eye Disease Market Disease Background and Overview

7. Dry Eye Disease Methodology

8. Dry Eye Disease Population

9. Dry Eye Disease Patient Journey

10. Dry Eye Disease Marketed Drugs

11. Dry Eye Disease Emerging Drugs

12. Dry Eye Disease – 7MM Market Analysis

13. Dry Eye Disease KOL Views

14. Dry Eye Disease Unmet Needs

15. Dry Eye Disease SWOT Analysis

16. Dry Eye Disease Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which include market analysis to accelerate business growth and overcome challenges with a practical approach.